Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 58Gastrointestinal 55Genitourinary 27Head & Neck 23Dermatologic 22Gynecologic 19Breast 13Lymphoid 5Other solid neoplasm 4CNS 3Sarcoma 2Endocrine 2NET 1

Conditions

Brain Neoplasms 2310Glioblastoma 2014Glioma 1399Central Nervous System Neoplasms 692Astrocytoma 667Neuroblastoma 647Gliosarcoma 480Neoplasms 405Oligodendroglioma 404Breast Neoplasms 327Medulloblastoma 307Carcinoma, Non-Small-Cell Lung 255Meningioma 229Recurrence 224Sarcoma 214Melanoma 206Neoplasm Metastasis 202Lung Neoplasms 199Ependymoma 199Neurofibromatosis 1 169Lymphoma 161Meningeal Carcinomatosis 138Osteosarcoma 134Ovarian Neoplasms 132Wilms Tumor 123Precursor Cell Lymphoblastic Leukemia-Lymphoma 123Head and Neck Neoplasms 117Lymphoma, Non-Hodgkin 116Diffuse Intrinsic Pontine Glioma 113Rhabdomyosarcoma 106

Interventions

pembrolizumab 2lenvatinib 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × CNS × Clear all
NCT03797326 2026-05-04

LEAP-005

Merck Sharp & Dohme LLC

Phase 2 Completed
611 enrolled 27 charts
BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05235737 2023-08-31

PIRG

Medical University of Silesia

Phase 4 Unknown
36 enrolled
CNS

Parkinson Disease 4, Autosomal Dominant Lewy Body, Glioblastoma

NCT02968940 2022-06-29

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

NYU Langone Health

Phase 2 Completed
6 enrolled 10 charts
CNS

Parkinson Disease 4, Autosomal Dominant Lewy Body, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡